- Learning Objective 1: Understand the curative nature of hematopoietic stem cell gene therapy with autologous transplant for primary immune deficiencies
- Learning Objective 2: Distinguish vector-mediated gene therapy from site-specific gene editing
- Learning Objective 3: Identify the benefits and risks of gene therapy versus gene editing
Session date:
02/03/2022 - 12:00pm to 1:00pm CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Caroline Kuo, MD